Results 41 to 50 of about 2,530 (165)

Diagnosis, Treatment and Prevention of Age-Related Macular Degeneration [PDF]

, 2022
In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the ...

core   +1 more source

Bioengineering of Antibody Fragments: Challenges and Opportunities. [PDF]

, 2023
Antibody fragments are used in the clinic as important therapeutic proteins for treatment of indications where better tissue penetration and less immunogenic molecules are needed.
Dolphin, Colin, Dolphin, Colin, Grabowska, Wiktoria Roksana, Grabowska, Wiktoria Roksana, Guiliano, David, Guiliano, David, Kashkoli, Hamid Heidari, Kashkoli, Hamid Heidari, Khalili, H., Khalili, H., Mirhassani, Reihaneh, Mirhassani, Reihaneh, Pirkalkhoran, Sama, Pirkalkhoran, Sama   +13 more
core   +4 more sources

Intravitreal brolucizumab as treatment of early onset radiation retinopathy secondary to plaque brachytherapy for choroidal melanoma

American Journal of Ophthalmology Case Reports, 2022
Purpose: To describe the efficacy and safety of brolucizumab (Beovu®, Novartis Pharmaceuticals) in a case of cystoid macular edema associated with radiation retinopathy as a result of iodine-125 plaque brachytherapy (PBT) for choroidal melanoma ...
Natacha C. Villegas, Kapil Mishra, Nathan Steinle, Wu Liu, Beth Beadle, Prithvi Mruthyunjaya   +5 more
doaj   +1 more source

One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization

Scientific Reports, 2022
We evaluated 1-year outcomes of loading phase treatment followed by maintenance treatment using a treat-and-extend (TAE) regimen with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) associated with type 1 macular ...
Hidetaka Matsumoto, Junki Hoshino, Ryo Mukai, Kosuke Nakamura, Hideo Akiyama   +4 more
doaj   +1 more source

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye

Case Reports in Ophthalmology, 2022
The efficacy of intravitreal anti-VEGF may be reduced in vitrectomized eyes due to accelerated drug clearance. Given its longer durability, brolucizumab may represent a suitable therapeutic option.
Emilia Maggio, Alessandro Alfano, Maurizio Mete, Grazia Pertile   +3 more
doaj   +1 more source

Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER

Ophthalmology and Therapy, 2023
Introduction The HAWK and HARRIER studies evaluated the efficacy and safety of brolucizumab versus aflibercept in treatment-naïve eyes with neovascular age-related macular degeneration.
Ramin Tadayoni, Glenn J. Jaffe, Frank G. Holz, Ursula Schmidt-Erfurth, Kanji Takahashi, Chui Ming Gemmy Cheung, Seenu M. Hariprasad, Kinfemichael Gedif, Rasmus Olsen, Catherine Best, Franklin Igwe, Peter K. Kaiser   +11 more
doaj   +1 more source

Novel and investigational therapies for wet and dry age-related macular degeneration [PDF]

, 2022
Funding Information: The authors are thankful to the Institute of Chemical Technology, Mumbai, India for providing facilities to carry out this work. V.J.is supported by a personal research grant from the Finnish Cultural Foundation (Ingrid, Toini and ...
Dyawanapelly, Sathish, Jayesh Sodha, Srushti, Junnuthula, Vijayabhaskarreddy, Kolimi, Praveen, Sarkar, Aira   +4 more
core   +1 more source

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration

Frontiers in Pharmacology, 2022
Purpose: To assess the morphological and functional outcomes within the first year of treatment with intravitreal brolucizumab for refractory neovascular age-related macular degeneration (nAMD).Methods: This retrospective study included 21 eyes from 19 ...
Alaa Din Abdin, Wissam Aljundi, Khalil El Jawhari, Shady Suffo, Isabel Weinstein, Berthold Seitz   +5 more
doaj   +1 more source

High-Yield Biosynthesis Process and Characterization of Brolucizumab

Pharmaceutical Fronts
Brolucizumab was the first single-chain fragment variable (scFv) antibody approved by the FDA for the treatment of age-related macular degeneration (AMD). However, the manufacturing process of brolucizumab remains rarely reported.
Xiaoyue Hu, Shuaiyi Huang, Tao Luo, Yapeng Wang, Jianguang Lu, Jun Feng   +5 more
doaj   +1 more source

Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis

Clinical Ophthalmology, 2023
Nicholas J Saba,1 Scott D Walter2 1Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, NY, USA; 2Retina Consultants, PC, Hartford, CT, USACorrespondence: Scott D Walter, Retina Consultants, PC, 43 Woodland Street, Hartford, CT, USA ...
Saba NJ, Walter SD
doaj